Content uploaded by John Corkery
Author content
All content in this area was uploaded by John Corkery on Jul 29, 2020
Content may be subject to copyright.
COVID-19: The Hidden Impact on
Mental Health and Drug Addiction
Stefania Chiappini
1
*, Amira Guirguis
1,2
*, Ann John
2
, John Martin Corkery
1
and Fabrizio Schifano
1
1
Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences,
University of Hertfordshire, Hatfield, United Kingdom,
2
Swansea University Medical School, Swansea University, Swansea,
United Kingdom
Keywords: COVID-19, addiction, mental health, drug abuse, prescription drug misuse
INTRODUCTION
There is concern the Coronavirus Disease (COVID)-19 pandemic is having a negative impact on the
mental health of the general population through a range of suggested mechanisms: fear, uncertainty,
and anxiety; social distancing/isolation; loneliness; and economic repercussions (1–3). Previous
disasters such as the Severe Acute Respiratory Syndrome (SARS) in 2003 (4–6) contributed to
increased anxiety, mood, and thought disorders, adjustment disorders, and post-traumatic stress
disorders (PTSD) (1,7–15), resulting, in extreme cases, in suicidal behaviours (e.g., suicidal ideation,
suicide attempts, and actual suicide) (10,16), especially in cases of concomitant Substance Use
Disorder (SUD) (17,18). According to a recent study from the Well Being Trust (18) the high levels
of stress, isolation and unemployment due to the COVID-19 pandemic could cause up to 75,000
“deaths of despair”related to deaths to drug, alcohol, and suicide (18). High risk of mental illness
was previously identified in individuals with existing or history of mental illnesses (1,9,12,14,19),
but also vulnerable categories might be considered the elderly (>80 years old), children/adolescents,
individuals from deprived areas, peri-natal women and BAME (Black, Asian and minority
ethnicities) (1,12,14,19). Finally, healthcare workers have been experiencing emotional
overload due to several reasons, including both organizational issues relating to the shortage of
suitable personal protective equipment, reduction in human resources and relentless work shifts
(20–23), but also the burden developed by the fear of becoming infected and infecting relatives, high
mortality rates, grieving the loss of patients and colleagues, separation from families (22–24).
Specifically, according to Huang et al. (25), among the first-line medical staff of a Tertiary Infectious
Disease Hospital for COVID-19 in China, the incidence of anxiety and post traumatic symptoms in
female medical staff was higher than that in male, and in nurses more represented than that in
doctors (25).
DISCUSSION
Often overlooked in this scenario are those with SUD (26,27), who may experience: (a) changes in
levels of drug use—an increase is often seen as a reactive behaviour to negative impact of disasters;
(b) a shift to other substances if access to those previously used become limited; (c) a relapse, if they
had already recovered from alcohol/drug addiction. Risks of severe COVID and intensified mental
Frontiers in Psychiatry | www.frontiersin.org July 2020 | Volume 11 | Article 7671
Edited by:
Fernando Barbosa,
University of Porto, Portugal
Reviewed by:
Domenico De Berardis,
Azienda Usl Teramo, Italy
Mercedes Lovrecic,
National Institute for Public Health,
Slovenia
*Correspondence:
Stefania Chiappini
stefaniachiappini9@gmail.com
Amira Guirguis
amira.guirguis@swansea.ac.uk
Specialty section:
This article was submitted to
Addictive Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 13 June 2020
Accepted: 20 July 2020
Published: 29 July 2020
Citation:
Chiappini S, Guirguis A, John A,
Corkery JM and Schifano F (2020)
COVID-19: The Hidden Impact on
Mental Health and Drug Addiction.
Front. Psychiatry 11:767.
doi: 10.3389/fpsyt.2020.00767
OPINION
published: 29 July 2020
doi: 10.3389/fpsyt.2020.00767
health issues in people who use drugs (PWUD) include: physical
comorbidity, e.g., lung or cardiovascular disease, HIV, viral
hepatitis infections; psychological comorbidity, e.g., general
distress, sleep disorders, anxiety/mood disorders, psychotic
symptoms; and homelessness, incarceration, economic
difficulties, and socioeconomic issues deriving from drug
addiction (8,11,27,28). Overdose risk for addicted people
who are home-isolating, and hence with typically no one to
inject them with naloxone, should be considered in a time of
overloaded emergency services and healthcare systems in general
(27,29). The COVID-19 pandemic is already impacting drug
markets, including shortages of numerous types of drugs at the
street level, price increases for consumers on the black market
and reductions in purity. Synthetic drugs’availability, such as
methamphetamine, is drastically reduced due to air travel
restrictions and flight cancellations, while cocaine, mostly
trafficked by sea, continues to be detected in European ports
during the pandemic (30). Heroin and opioids seem to be
pushed toward being trafficked along maritime routes. Finally,
cannabis appears to be less available, due to restrictions on
movement across regions and borders under coronavirus
lockdown. These disruptions are likely to grow and further
increase risks for people who use drugs, for example by
increasing variability in drug purity, the likelihood of
adulteration, and contamination of heroin supply with
synthetic opioids, such as fentanyl. These issues can also
encourage shifts to more at-risk drug using behaviours such as
use of drugs such as street benzodiazepines, and synthetic
cannabinoids (31). Additionally, the COVID-19 crisis is likely
to increase the need to access drug treatment and services, e.g.,
extra demand for opioid substitution therapy and other
medication. Access to drug services is being disrupted by self-
quarantine, social distancing and other public health measures
adopted for dealing with COVID-19 (27,29,31). Similarly,
community pharmacies are challenged by staff shortages,
service disorganisation, and self-isolation (27,29,32).
In response to the long-lasting and wide-ranging challenging
effects of the pandemic (5,12,19,27,29), some harm-avoiding
interventions have been adopted, including: more flexible take-
home-medication treatment programmes for opioid addicted
patients (33,34); guidance for facilitating controlled substance
prescribing (26,29,35); tele-health for monitoring drug-
dependent patients; and access to virtual support groups
through online meetings (15,26,32). Conversely, both peer-
support groups and rehabilitation facilities have suspended
programmes and limited new admissions (27,32). Hollander &
Carr (36) compared and contrasted the acceptability and impact
of telemedicine versus in-person consultations. During the
COVID pandemic, telehealth has demonstrated to enable
continuity of services, while protecting service providers from
infection. However, in-person consultations are still needed for
certain groups of patients where maintenance in treatment is
at risk.
In this context, due to the disruption of drug markets,
reduced supply and access to illicit drugs, internet drug-
seeking activities may be on the increase. In line with this,
rogue/illicit pharmaceutical products, such as benzodiazepines,
has also reportedly doubled their prices in some areas (24).
Alternative drugs or medications might be considered by users
including quetiapine, gabapentinoids, Z-drugs (e.g., zolpidem)
(37–39) and some Over-The-Counter (OTC) medications (37,
38), such as codeine; ephedrine and pseudoephedrine; and the
antidiarrhoeal loperamide (“poor man’s methadone”).
IMPLICATIONS IN PRACTICE
Interventions addressing the health, psychological, and social
effects of the pandemic are required. Healthcare professionals
have an important role in educating patients about the common
psychological effects of a pandemic. COVID-19, together with
general environmental factors, such as stress or trauma, may
contribute to both a mental illness and a SUD developing. A
proactive approach to upscale our mental health care, emergency
preparedness and response for people with SUDs is urgently
needed; mental health services should develop and evaluate: clear
remote assessment; care pathways for people at risk; psycho-
education strategies, regarding self-harm/suicide, overdoses, and
domestic violence; and staff training to support new ways of
working (1,7,12). Healthcare providers, including pharmacists,
and public health policies are challenged to: develop strategies to
implement prevention measures against transmission of COVID-19
in drug users settings, such as preventing overcrowding or sharing
drug-using equipment; and ensure continuity of care for drug-users
and people with SUDs. Specifically, access to community
maintenance, e.g., expand methadone delivery via mobile teams
for quarantined patients should be facilitated (40,41). Monitoring
psychosocial needs and delivering psychosocial support to
vulnerable patients as well as healthcare workers should be
provided (2,3,8,42,43). It is crucial to strengthen telemedicine
and support it with appropriate governance and funding in order to
be able to monitor the mental health situation post-pandemic.
Supporting healthcare workers with appropriate equipment,
training on telehealth and caring for their safety with respect to
protection against infection and spread of infection, preventing
violence and burglary in drug treatment services, pharmacies would
enable robust support against a possible mental health wave post-
pandemic. Prescribers and pharmacists should be warned about:
possible requests to prescribe more drugs than needed to take home;
excessive sales of prescription/OTC products which might be
diverted and abused; and aggression toward staff. Developing
multidisciplinary support platforms could be helpful in reducing
the mental distress due to misinformation and teaching problem-
solving strategies to cope with the pandemic (13).
AUTHOR CONTRIBUTIONS
The opinion was developed by all authors. SC drafted the first
version of the manuscript with input from all authors. All authors
contributed to the article and approved the submitted version.
Chiappini et al. COVID-19: Impact on Mental Health and Drug
Frontiers in Psychiatry | www.frontiersin.org July 2020 | Volume 11 | Article 7672
REFERENCES
1. Gunnell D, Appleby L, Arensman E, Hawton K, John A, Kapur N, et al.
Suicide risk and prevention during the COVID-19 pandemic. Lancet
Psychiatry (2020) 7(6):468–71. doi: 10.1016/S2215-0366(20)30171-1
2. Holmes EA, O’Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al.
Multidisciplinary research priorities for the COVID-19 pandemic: a call for
action for mental health science. Lancet Psychiatry (2020) 7(6):547–60.
doi: 10.1016/S2215-0366(20)30168-1
3. Smith K, Ostinelli E, Cipriani A. Covid-19 and mental health: a
transformational opportunity to apply an evidence-based approach to
clinical practice and research. Evid Based Ment Health (2020) 23(2):45–6.
doi: 10.1136/ebmental-2020-300155
4. Chan SM, Chiu FK, Lam CW, Leung PY, Conwell Y. Elderly suicide and the
2003 SARS epidemic in Hong Kong. Int J Geriatr Psychiatry (2006) 21
(2):113–8. doi: 10.1002/gps.1432
5. Chevance A, Gourion D, Hoertel N, Llorca PM, Thomas P, Bocher R, et al.
Ensuring mental health care during the SARS-CoV-2 epidemic in France: A
narrative review. Encephale (2020) 46(3S):S3–S13. doi: 10.1016/
j.encep.2020.04.005
6. Substance Abuse and Mental Health Services Administration (SAMHSA).
SAMHSA Disaster Technical Assistance Center. Supplemental Research
Bulletin. Issue 5: Traumatic Stress and Suicide After Disasters (2015).
https://www.samhsa.gov/sites/default/files/dtac/srb_sept2015.pdf (Accessed
May19, 2020).
7. Courtet P, OliéE, Debien C, Vaiva G. Keep socially (but not physically)
connected and carry on: preventing suicide in the age of COVID-19. J Clin
Psychiatry (2020) 81(3):20com13370. doi: 10.4088/JCP.20com13370
8. GOV.UK. COVID-19 mental health campaign launches (2020). https://www.
gov.uk/government/news/covid-19-mental-health-campaign-launches
(Accessed May 19, 2020).
9. Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients
experience more psychiatric symptoms during COVID-19 pandemic and
lockdown? A case-control study with service and research implications for
immunopsychiatry. Brain Behav Immun (2020) 87:100–6. doi: 10.1016/
j.bbi.2020.04.069
10. Mamun MA, Griffiths MD. First COVID-19 suicide case in Bangladesh due to
fear of COVID-19 and xenophobia: Possible suicide prevention strategies.
Asian J Psychiatr (2020) 51:102073. doi: 10.1016/j.ajp.2020.102073
11. Pfefferbaum B, North CS. Mental Health and the Covid-19 Pandemic. N Eng J
Med (2020). doi: 10.1056/NEJMp2008017
12. Reger MA, Stanley IH, Joiner TE. Suicide Mortality and Coronavirus Disease
2019—A Perfect Storm? JAMA Psychiatry (2020). doi: 10.1001/
jamapsychiatry.2020.1060
13. Rajkumar RP. COVID-19 and mental health: A review of the existing
literature. Asian J Psychiatr (2020) 52:102066. doi: 10.1016/j.ajp.2020.102066
14. Thakur V, Jain A. COVID 2019-Suicides: A global psychological pandemic.
Brain Behav Immun (2020) 0889–1591(20):30643–7. doi: 10.1016/
j.bbi.2020.04.062
15. WHO. Mental health and psychosocial considerations during COVID-19
outbreak (2020). https://www.who.int/docs/default-source/coronaviruse/
mental-health-considerations.pdf (Accessed May 24, 2020).
16. Griffiths MD, Mamun MA. COVID-19 suicidal behavior among couples and
suicide pacts: Case study evidence from press reports. Psychiatry Res (2020)
289:113105. doi: 10.1016/j.psychres.2020.113105
17. Dsouza DD, Quadros S, Hyderabadwala ZJ, Mamun MA. Aggregated
COVID-19 suicide incidences in India: Fear of COVID-19 infection is the
prominent causative factor. Psychiatry Res (2020) 28:113145. doi: 10.1016/
j.psychres.2020.113145
18. Petterson S, Westfall J, Miller BF. Projected Deaths of Despair During the
Coronavirus Recession. Well Being Trust (2020) 8:2020. WellBeingTrust.org.
19. Wand APF, Zhong B-L, Chiu HFK, Draper B, De Leo D. Covid-19: The
implications for suicide in older adults. Int Psychogeriatr (2020), 16.
doi: 10.1017/S1041610220000770
20. CDC, 2020; Centers for Disease Control and Prevention (CDC). Healthcare
Personnel and First Responders: How to Cope with Stress and Build Resilience
During the COVID-19 Pandemic (2020). https://www.cdc.gov/coronavirus/
2019-ncov/hcp/mental-health-healthcare.html (Accessed July 7, 2020).
21. Epidemiology for public health. Istituto Superiore di Sanità. COVID-19: stress
management among healthcare workers (2020). https://www.epicentro.iss.it/
en/coronavirus/sars-cov-2-stress-management-healthcare-workers (Accessed
July 7, 2020).
22. Walton M, Murray E, Christian MD. Mental health care for medical staff and
affiliated healthcare workers during the COVID-19 pandemic. Eur Heart J
Acute Cardiovasc Care (2020) 9(3):241–7. doi: 10.1177/2048872620922795
23. Wu K, Wei X. Analysis of Psychological and Sleep Status and Exercise
Rehabilitation of Front-Line Clinical Staff in the Fight Against COVID-19
in China. Med Sci Monit Basic Res (2020) 26:e924085. doi: 10.12659/
MSMBR.924085
24. Zhuo K, Gao C, Wang X, Zhang C, Wang Z. Stress and sleep: a survey based
on wearable sleep trackers among medical and nursing staff in Wuhan during
the COVID-19 pandemic. Gen Psychiatr (2020) 33(3):e100260. doi: 10.1136/
gpsych-2020-100260
25. Huang JZ, Han MF, Luo TD, Ren AK, Zhou XP. Mental health survey of
medical staff in a tertiary infectious disease hospital for COVID-19. Zhonghua
Lao Dong Wei Sheng Zhi Ye Bing Za Zhi (2020) 38(3):192–5. doi: 10.3760/
cma.j.cn121094-20200219-00063
26. Drug Enforcement Administration (DEA). COVID-19 information page
(2020). www.deadiversion.usdoj.gov/coronavirus.html. (Accessed May 21,
2020)
27. European Monitoring Centre for Drug and Drug Addiction (EMCDDA). The
implications of COVID-19 for people who use drugs (PWUD) and drug service
providers (March 2020). http://www.emcdda.europa.eu/publications/topic-
overviews/covid-19-and-people-who-use-drugs_en (Accessed May 19, 2020).
28. Zhu S, Wu Y, Zhu CY, Hong WC, Yu ZX, Chen ZK, et al. The immediate
mental health impacts of the COVID-19 pandemic among people with or
without quarantine managements. Brain Behav Immun (2020) 87:56–8.
doi: 10.1016/j.bbi.2020.04.045
29. Volkow ND. Collision of the COVID-19 and Addiction Epidemics. Ann
Intern Med (2020a) 173(1):61–2. doi: 10.7326/M20-1212
30. United Nations (UN). COVID-19 causes some illegal drug prices to surge, as
supplies are disrupted worldwide (2020). https://news.un.org/en/story/2020/
05/1063512 (Accessed May 25, 2020).
31. Volkow ND. Coping with the Collision of Public Health Crises: COVID-19 and
Substance Use Disorders (2020b). NIH Director’s Blog with Dr. Volkow.
https://directorsblog.nih.gov/2020/04/21/coping-with-the-collision-of-
public-health-crises-covid-19-and-substance-use-disorders/ (Accessed May
19, 2020).
32. Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19
pandemic: A call to sustain regulatory easements and further expand access to
treatment. Subst Abus (2020) 41(2):147–9. doi: 10.1080/08897077.2020.1752351
33. Advisory Council on the Misuse of Drugs (ACMD). COVID-19: ACMD advice
on proposed legislative changes to enable supply of controlled drugs during a
pandemic (April 2020). https://www.gov.uk/government/publications/acmd-
advice-on-covid-19-emergency-legislation-to-enable-supply-of-controlled-
drugs (Accessed May 21, 2020).
34. Substance Abuse and Mental Health Services Administration (SAMHSA).
FAQs: Provision of methadone and buprenorphine for the treatment of opioid
use disorder in the COVID-19 emergency (2020). https://www.samhsa.gov/
sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf (Accessed
May19, 2020).
35. Levander XA, Wakeman SE. Covid-19 will worsen the opioid overdose crisis is
we don"t prepare now (2020). STAT. https://www.statnews.com/2020/03/17/
covid-19-will-worsen-the-opioid-overdose-crisis-if-we-dont-prepare-now/
(Accessed May 25, 2020).
36. Hollander JE, Carr BG. Virtually perfect? Telemedicine for COVID-19. New
Engl J Med (2020) 382(18):1679–81. doi: 10.1056/NEJMp2003539
37. Levine DA. “Pharming”: the abuse of prescription and over-the-counter drugs
in teens. Curr Opin Pediatr (2007) 19(3):270–4. doi: 10.1097/
MOP.0b013e32814b09cf
38. Reeves RR, Ladner ME, Perry CL, Burke RS, Laizer JT. Abuse of medications
that theoretically are without abuse potential. South Med J (2015) 108(3):151–
7. doi: 10.14423/smj.0000000000000256
39. Schifano F. Recent Changes in Drug Abuse Scenarios: The New/Novel
Psychoactive Substances (NPS) Phenomenon. Brain Sci (2018) 8(12):221.
doi: 10.3390/brainsci8120221
Chiappini et al. COVID-19: Impact on Mental Health and Drug
Frontiers in Psychiatry | www.frontiersin.org July 2020 | Volume 11 | Article 7673
40. Becker WC, Fiellin DA. When Epidemics Collide: Coronavirus Disease 2019
(COVID-19) and the Opioid Crisis. Ann Intern Med (2020) 173(1):59–60.
doi: 10.7326/M20-1210
41. Simeone R. Doctor Shopping Behavior and the Diversion of Prescription
Opioids. Subst Abuse (2017) 11:1178221817696077. doi: 10.1177/
1178221817696077
42. Kawohl W, Nordt C. COVID-19, unemployment, and suicide. Lancet
Psychiatry (2020) 7(5):389–90. doi: 10.1016/S2215-0366(20)30141-3
43. Klomek AB. Suicide prevention during the COVID-19 outbreak. Lancet
Psychiatry (2020) 7(5):390. doi: 10.1016/S2215-0366(20)30142-5
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Chiappini, Guirguis, John, Corkery and Schifano. This is an open-
access article distributed under the termsof the Creative Commons Attribution License
(CC BY). The use, di stribution or reproduction in other forums is permitt ed, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Chiappini et al. COVID-19: Impact on Mental Health and Drug
Frontiers in Psychiatry | www.frontiersin.org July 2020 | Volume 11 | Article 7674